Lars Fruergaard Jørgensen As chief executive of Novo Nordisk from 2017 until earlier this month, I had a front-row seat to the promise and limitations of pharmaceutical interventions. These ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the National Pharmacy Association.

Novo Nordisk A/S (NYSE:NVO) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Novo Nordisk A/S (NYSE:NVO) ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...

Shares of WW International Inc., the company known as WeightWatchers, reversed their early gains Monday despite better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity ...

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, ...

Cornell University researchers have developed an implant system that can treat Type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Corporate lobbying shop Ballard Partners previously employed Donald Trump’s chief of staff as well as his attorney general.

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...